Insilico Medicine completes first patient dosing in Phase 1 trial of NLRP3 inhibitor ISM8969

• Insilico Medicine Cayman Topco dosed the first participant in a Phase 1 study of ISM8969, an oral NLRP3 inhibitor developed with HengTai Bio.
• No clinical results have been presented; the announcement covers trial initiation and first-in-human dosing.
• The study is designed to assess safety and tolerability in healthy volunteers and obese adults with cardiovascular risk.
• Insilico granted HengTai Bio global rights to develop and commercialize ISM8969; the partners split worldwide economics 50%-50%.
• The deal includes up to USD 66 million in upfront and milestone payments to Insilico.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260617-12205809), on June 17, 2026, and is solely responsible for the information contained therein.